Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Terns Pharmaceuticals (TERN) Accumulated Expenses (2020 - 2025)

Terns Pharmaceuticals filings provide 6 years of Accumulated Expenses readings, the most recent being $14.2 million for Q4 2025.

  • Quarterly Accumulated Expenses rose 8.73% to $14.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $14.2 million through Dec 2025, up 8.73% year-over-year, with the annual reading at $14.2 million for FY2025, 8.73% up from the prior year.
  • Accumulated Expenses hit $14.2 million in Q4 2025 for Terns Pharmaceuticals, up from $12.0 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $14.2 million in Q4 2025 and bottomed at $953000.0 in Q2 2021.
  • Average Accumulated Expenses over 5 years is $7.4 million, with a median of $7.9 million recorded in 2023.
  • The largest annual shift saw Accumulated Expenses plummeted 47.88% in 2021 before it skyrocketed 370.62% in 2022.
  • Terns Pharmaceuticals' Accumulated Expenses stood at $4.7 million in 2021, then decreased by 18.13% to $3.8 million in 2022, then skyrocketed by 129.66% to $8.8 million in 2023, then skyrocketed by 48.13% to $13.1 million in 2024, then rose by 8.73% to $14.2 million in 2025.
  • Per Business Quant, the three most recent readings for TERN's Accumulated Expenses are $14.2 million (Q4 2025), $12.0 million (Q3 2025), and $9.6 million (Q2 2025).